Alasdair MacGowan

14.7k total citations · 1 hit paper
284 papers, 8.4k citations indexed

About

Alasdair MacGowan is a scholar working on Pharmacology, Molecular Medicine and Epidemiology. According to data from OpenAlex, Alasdair MacGowan has authored 284 papers receiving a total of 8.4k indexed citations (citations by other indexed papers that have themselves been cited), including 139 papers in Pharmacology, 116 papers in Molecular Medicine and 89 papers in Epidemiology. Recurrent topics in Alasdair MacGowan's work include Antibiotics Pharmacokinetics and Efficacy (138 papers), Antibiotic Resistance in Bacteria (116 papers) and Bacterial Identification and Susceptibility Testing (64 papers). Alasdair MacGowan is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (138 papers), Antibiotic Resistance in Bacteria (116 papers) and Bacterial Identification and Susceptibility Testing (64 papers). Alasdair MacGowan collaborates with scholars based in United Kingdom, Netherlands and Spain. Alasdair MacGowan's co-authors include Karen E. Bowker, Timothy R. Walsh, Mandy Wootton, Peter M. Bennett, Alan Noel, H. A. Holt, Johan W. Mouton, Rafael Cantón, Gunnar Kahlmeter and Martin Steinbakk and has published in prestigious journals such as The Lancet, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Alasdair MacGowan

278 papers receiving 8.0k citations

Hit Papers

EUCAST expert rules in an... 2011 2026 2016 2021 2011 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. EUCAST expert rules in antimicrobial susceptibility testing
    2011 502 citations Rafael Cantón, Christian G. Giske et al. Clinical Microbiology and Infection profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Alasdair MacGowan United Kingdom 47 2.8k 2.8k 2.3k 2.2k 1.6k 284 8.4k
George H. Talbot United States 44 2.4k 0.8× 3.6k 1.3× 2.5k 1.1× 3.7k 1.7× 1.6k 1.0× 120 10.1k
Winfried V. Kern Germany 55 1.4k 0.5× 2.6k 1.0× 3.1k 1.4× 3.0k 1.4× 2.0k 1.2× 289 10.1k
Helen W. Boucher United States 34 2.2k 0.8× 3.8k 1.4× 2.2k 1.0× 3.3k 1.5× 1.7k 1.0× 89 10.4k
David J. Farrell United States 54 2.0k 0.7× 2.9k 1.0× 3.3k 1.4× 2.8k 1.3× 1.3k 0.8× 268 8.9k
David M. Shlaes United States 47 1.5k 0.5× 2.6k 1.0× 1.9k 0.9× 2.6k 1.2× 1.5k 0.9× 131 8.0k
David N. Gilbert United States 43 3.1k 1.1× 4.1k 1.5× 2.8k 1.2× 2.2k 1.0× 1.5k 0.9× 142 12.1k
Javier Garau Spain 53 1.4k 0.5× 2.2k 0.8× 4.8k 2.1× 2.3k 1.0× 1.1k 0.7× 208 10.9k
Romney M. Humphries United States 48 1.3k 0.5× 2.8k 1.0× 1.5k 0.7× 2.1k 1.0× 2.0k 1.2× 232 6.8k
Otto Cars Sweden 52 4.3k 1.5× 4.5k 1.6× 3.1k 1.4× 1.5k 0.7× 1.1k 0.7× 186 9.9k
Ethan Rubinstein Canada 45 1.8k 0.6× 1.8k 0.6× 2.4k 1.1× 2.4k 1.1× 877 0.5× 140 6.8k

Countries citing papers authored by Alasdair MacGowan

Since Specialization
Citations

This map shows the geographic impact of Alasdair MacGowan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alasdair MacGowan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alasdair MacGowan more than expected).

Fields of papers citing papers by Alasdair MacGowan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alasdair MacGowan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alasdair MacGowan. The network helps show where Alasdair MacGowan may publish in the future.

Co-authorship network of co-authors of Alasdair MacGowan

This figure shows the co-authorship network connecting the top 25 collaborators of Alasdair MacGowan. A scholar is included among the top collaborators of Alasdair MacGowan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alasdair MacGowan. Alasdair MacGowan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
MacGowan, Alasdair, et al.. (2025). The pharmacodynamics of fosfomycin in combination with meropenem against Klebsiella pneumoniae studied in an in vitro model of infection. Journal of Antimicrobial Chemotherapy. 80(4). 967–975. 2 indexed citations
2.
Berg, Sanne van den, Marie Attwood, Anouk E. Muller, et al.. (2025). Pharmacodynamics of NOSO-502 studied in vitro and in vivo: determination of the dominant pharmacodynamic index driver. Journal of Antimicrobial Chemotherapy. 80(3). 752–759. 2 indexed citations
3.
Hamilton, Fergus, et al.. (2024). Trends in fluoroquinolone prescribing in UK primary and secondary care between 2019 and 2023. Journal of Antimicrobial Chemotherapy. 80(2). 518–527.
4.
Arnold, David, Fergus Hamilton, Jessica Hughes, et al.. (2024). Antibiotic pharmacokinetics in infected pleural effusions. Thorax. 79(9). 883–885. 3 indexed citations
5.
MacGowan, Alasdair, Marie Attwood, Alan Noel, et al.. (2023). Exposure of Escherichia coli to antibiotic-efflux pump inhibitor combinations in a pharmacokinetic model: impact on bacterial clearance and drug resistance. Journal of Antimicrobial Chemotherapy. 78(12). 2869–2877. 3 indexed citations
6.
Hamilton, Fergus, Matt Thomas, David Arnold, et al.. (2023). Therapeutic potential of IL6R blockade for the treatment of sepsis and sepsis-related death: A Mendelian randomisation study. PLoS Medicine. 20(1). e1004174–e1004174. 69 indexed citations
7.
8.
9.
Schubert, H., Jacqueline Findlay, Virginia C. Gould, et al.. (2021). Limited phylogenetic overlap between fluoroquinolone-resistant Escherichia coli isolated on dairy farms and those causing bacteriuria in humans living in the same geographical region. Journal of Antimicrobial Chemotherapy. 76(12). 3144–3150. 12 indexed citations
10.
Alorabi, Mohammed, Fergus Hamilton, Yuiko Takebayashi, et al.. (2021). Trade-Offs between Antibacterial Resistance and Fitness Cost in the Production of Metallo-β-Lactamases by Enteric Bacteria Manifest as Sporadic Emergence of Carbapenem Resistance in a Clinical Setting. Antimicrobial Agents and Chemotherapy. 65(8). e0241220–e0241220. 9 indexed citations
11.
Findlay, Jacqueline, et al.. (2019). Characterization of cefotaxime-resistant urinary Escherichia coli from primary care in South-West England 2017–18. Journal of Antimicrobial Chemotherapy. 75(1). 65–71. 38 indexed citations
12.
Lovering, Andrew, et al.. (2019). Anin vitrobiofilm model ofStaphylococcus aureusinfection of bone. Letters in Applied Microbiology. 68(4). 294–302. 14 indexed citations
13.
Kluytmans, Jan, Christian G. Giske, Alasdair MacGowan, et al.. (2019). Obituary: Johan Willem Mouton. Clinical Microbiology and Infection. 26(1). 125–126. 1 indexed citations
14.
Takebayashi, Yuiko, Jacqueline Findlay, Kate J. Heesom, et al.. (2018). Prediction of Fluoroquinolone Susceptibility Directly from Whole-Genome Sequence Data by Using Liquid Chromatography-Tandem Mass Spectrometry To Identify Mutant Genotypes. Antimicrobial Agents and Chemotherapy. 62(3). 15 indexed citations
15.
Gomila‐Grange, Aina, Jordi Carratalà, Noa Eliakim‐Raz, et al.. (2018). Risk factors and prognosis of complicated urinary tract infections caused by Pseudomonas aeruginosa in hospitalized patients: a retrospective multicenter cohort study. SHILAP Revista de lepidopterología. 2 indexed citations
16.
Evans, David, et al.. (2017). Extent, quality and impact of patient and public involvement in antimicrobial drug development research: A systematic review. Health Expectations. 21(1). 75–81. 17 indexed citations
17.
Mouton, Johan W., Paul G. Ambrose, Rafael Cantón, et al.. (2011). Conserving antibiotics for the future: New ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective. Drug Resistance Updates. 14(2). 107–117. 156 indexed citations
18.
MacGowan, Alasdair. (2008). Breakpoints for extended-spectrum β-lactamase-producing Enterobacteriacae: pharmacokinetic/pharmacodynamic considerations. Clinical Microbiology and Infection. 14. 166–168. 18 indexed citations
19.
Whitehouse, Tony, et al.. (2002). The Pharmacokinetic Profiles of Linezolid and Teicoplanin in the critically ill. UCL Discovery (University College London). 1 indexed citations
20.
Winter, Robbert J. de, et al.. (1992). A controlled trial of selective decontamination of the digestive tract in intensive care and its effect on nosocomial infection. Journal of Antimicrobial Chemotherapy. 30(1). 73–87. 71 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by George H. Talbot Breakdown of academic impact, for papers by Winfried V. Kern Breakdown of academic impact, for papers by Helen W. Boucher Breakdown of academic impact, for papers by David J. Farrell Breakdown of academic impact, for papers by David M. Shlaes Breakdown of academic impact, for papers by David N. Gilbert Breakdown of academic impact, for papers by Javier Garau Breakdown of academic impact, for papers by Romney M. Humphries Breakdown of academic impact, for papers by Otto Cars Breakdown of academic impact, for papers by Ethan Rubinstein
Rankless by CCL
2026